Items Tagged ‘Metastatic Breast Cancer’

October 5, 2017

FDA approves new treatment for certain advanced or metastatic breast cancers

By

The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones (endocrine therapy). Verzenio is approved to be given in combination with an endocrine […]

View full entry

Tags: abemaciclib, Breast Cancer, fulvestrant, hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, Metastatic Breast Cancer, News, Precision Cancer Medicine, Verzenio


September 29, 2015

No Benefit with Addition of Onartuzumab to Taxol® with or without Avastin® in Triple-Negative Breast Cancer

By

The addition of the targeted therapy onartuzumab to Taxol® (paclitaxel) with or without Avastin® (bevacizumab) does not appear to help control disease or improve survival in patients with metastatic triple-negative breast cancer. These findings were published in the Annals of Oncology. The majority of breast cancers are hormone receptor-positive, meaning that the cancer cells are […]

View full entry

Tags: avastin, Breast Cancer, metastatic, Metastatic Breast Cancer, Onatuzumab, Taxol, triple negative


June 28, 2013

Afinitor Provides Benefit in Advanced, HER2-Positive Breast Cancer

By

Among women with advanced HER2-positive breast cancer and resistance to Herceptin® (trastuzumab), a treatment regimen that included Afinitor® (everolimus) delayed cancer progression. The results of this Phase III clinical trial were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO). Afinitor is an oral medication that works by inhibiting a […]

View full entry

Tags: Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer


March 28, 2011

Diagnosis of Early Breast Cancer Doesn’t Shorten Life Expectancy of Older Women

By

Among women age 67 or older, a diagnosis of ductal carcinoma in situ (DCIS) or Stage I breast cancer doesn’t appear to worsen survival; survival is similar to that of older women without breast cancer. Diagnosis of more advanced breast cancer, however, is linked with worse survival. These results were published in the Journal of […]

View full entry

Tags: Breast Cancer, Carcinoma In Situ Breast cancer, Metastatic Breast Cancer, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer


January 26, 2011

Social Support May Improve Breast Cancer Outcomes

By

Social well-being during the first year after a breast cancer diagnosis may have a beneficial effect on cancer outcomes. These results were published in the Journal of Clinical Oncology. A diagnosis of breast cancer often affects a woman’s quality of life, but it’s been less clear whether quality of life affects breast cancer outcomes. Quality […]

View full entry

Tags: Breast Cancer, Carcinoma In Situ Breast cancer, Inflammatory Breast Cancer, Metastatic Breast Cancer, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, Supportive Care, Supportive Care Breast Cancer


November 30, 2010

Xgeva Approved for Patients with Bone Metastases

By

Xgeva™ (denosumab) has been approved by the US Food and Drug Administration (FDA) for the prevention of bone complications such as fracture in patients with bone metastases from solid (not blood-related) cancers. It is not approved for patients with multiple myeloma or other cancers of the blood. Metastatic cancer refers to cancer that has spread […]

View full entry

Tags: Breast Cancer, Management and Prevention of Bone Complications Supportive Care, Metastatic Breast Cancer, Metastatic Stage IV (D) Prostate Cancer, Prostate Cancer, Supportive Care


October 30, 2008

Number of Circulating Cancer Cells Associated with Survival in Advanced Breast Cancer

By

Number of Circulating Cancer Cells Associated with Survival in Advanced Breast Cancer Cancer cells found circulating in the blood are a strong predictor of mortality among patients with metastatic breast cancer. Patients with large numbers of cancer cells found circulating in the blood may benefit from more aggressive or novel therapeutic approaches. These results were […]

View full entry

Tags: Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer


October 22, 2008

Aromasin® and Nolvadex® Both Effective as Initial Therapy for Hormone-Positive Breast Cancer

By

Aromasin® and Nolvadex® Both Effective as Initial Therapy for Hormone-Positive Breast Cancer Both Aromasin (exemestane) and Nolvadex (tamoxifen) are effective as initial therapy for metastatic breast cancer among postmenopausal women. These results were recently published in the Journal of Clinical Oncology. Women with hormone-positive breast cancer have cancer that is stimulated to grow from exposure […]

View full entry

Tags: Breast Cancer, Metastatic Breast Cancer